Atyr_Logo.png
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
03. Juni 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
Atyr_Logo.png
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24. Mai 2024 16:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atyr_Logo.png
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
15. Mai 2024 07:00 ET | aTyr Pharma, Inc.
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
Atyr_Logo.png
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
14. Mai 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Atyr_Logo.png
aTyr Pharma to Present at Upcoming Investor Conferences
06. Mai 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma to present at upcoming investor conferences.
Atyr_Logo.png
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
02. Mai 2024 16:00 ET | aTyr Pharma, Inc.
aTyr Pharma announces first quarter 2024 results and provides corporate update
Atyr_Logo.png
aTyr Pharma to Participate in April Investor Conferences
01. April 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma to Participate in April Investor Conferences
Atyr_Logo.png
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
14. März 2024 16:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
Atyr_Logo.png
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
28. Februar 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
Atyr_Logo.png
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
21. Februar 2024 08:00 ET | aTyr Pharma, Inc.
Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants